Understand the source comparison
Comparison Table: AOD-9604 Tesofensine Protocol vs Single-Agent Approaches
The following table compares the dual-pathway protocol against individual compound use across key research parameters: AOD-9604 alone Beta-3 adrenergic receptor agonism → lipolysis 300–500 mcg twice daily (SC) 3.2–4.1% body fat reduction Minimal to none. May i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the dual-pathway protocol against individual compound use across key research parameters:
- AOD-9604 alone
- Beta-3 adrenergic receptor agonism → lipolysis
- 300–500 mcg twice daily (SC)
- 3.2–4.1% body fat reduction
- Minimal to none. May increase compensatory hunger
- Metabolic rate studies, lipolysis pathway research, GH fragment investigations
- Effective for fat mobilization but requires strict caloric control. Without appetite management, results are inconsistent
- Tesofensine alone
- Triple monoamine reuptake inhibition (DA/NE/5-HT)
- 0.25–0.5 mg once daily (oral)
- 5.8–7.2% body weight reduction
- Significant. Reduces intake by 15–25% vs baseline
- Appetite regulation research, satiety signaling studies, obesity pharmacology
- Strong appetite suppression but limited metabolic enhancement. Fat loss depends entirely on caloric deficit created
- AOD-9604 + Tesofensine (dual protocol)
- Peripheral lipolysis + central appetite suppression
- 300–500 mcg AOD twice daily + 0.5 mg tesofensine daily
- 8.7–11.3% body fat reduction
- Maintained. Tesofensine prevents compensatory intake
- Dual-pathway fat loss research, metabolic-behavioral intervention studies, protocol optimization trials
- Most comprehensive approach. Addresses both sides of energy balance simultaneously and prevents the plateau effect seen with single-agent protocols